Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 37 for your search:
Drug:
MART-1 antigen
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of Sargramostim (GM-CSF) and Peptide Vaccination Comprising Tyrosinase:368-376, gp100:209-217 (210M) Antigen, and MART-1:27-35 Peptide Versus Peptide Vaccination Alone Versus GM-CSF Alone Versus Placebo in Patients With Locally Advanced or Metastatic Melanoma
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-4697
, SWOG-E4697, E4697, NCT00005034
2.
Phase III Randomized Study of Adjuvant NA17-A and Melanoma Differentiation Peptides in HLA-A2-Positive Patients With Primary Ocular Melanoma at High Risk of Relapse
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
Over 18
Sponsor:
Other
Protocol IDs:
EORTC-18001
, EORTC-88001, NCT00036816
3.
Phase I/II Study of Immunization With Dendritic Cells Presenting Epitopes Derived from the Melanoma Associated Antigens MART-1 and gp100 With or Without Interleukin-2 in Patients With Metastatic Melanoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-97-C-0046
, NCI-97-C-0019, NCI-T96-0046N, T96-0046, NCT00019214
4.
Phase I/II Study of Immunization with MAGE-3 or Melan-A Peptide-Pulsed Autologous Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 in Patients with Metastatic Melanoma (Summary Last Modified 02/2002)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
Not specified
Sponsor:
NCI
Protocol IDs:
UCCRC-9018
, UCCRC-8381, NCI-G97-1162, NCT00002952
5.
Phase I/II Study of Ad2/MART-1v2 and Ad2/gp100v2 Melanoma Antigen Vaccines in Patients With Stage II, III, or IV Melanoma (Summary Last Modified 07/2002)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GENZ-ADVMEL-001-99
, DFCI-00069, GENZ-2000-P-000380/1, NCT00010309
6.
Phase II Study of Immunization Comprising Immunodominant Peptides from 3 Melanoma Antigens (MART-1, gp100, and Tyrosinase) in Patients With Refractory Metastatic Melanoma (Summary Last Modified 10/2000)
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-98-C-0023
, NCI-T97-0089, T97-0089
7.
Phase II Study of Flt3 Ligand Alone or in Combination With Melanoma Peptide Immunization in Patients With Metastatic Melanoma or Renal Cell Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
Not specified
Sponsor:
NCI
Protocol IDs:
NCI-98-C-0040
, NCI-T97-0092, T97-0092, NCT00019396
8.
Phase II Study of MART-1 and gp100 Peptides Modified to Increase Binding to HLA-A0201 With or Without Interleukin-2 in Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-99-C-0092
, NCI-T99-0033, T99-0033, NCT00019721
9.
Phase II Study of Immunization Using gp100:44-59, gp100:209-217 (210M), and MART-1:26-35 (27L) Antigen Peptides in HLA-DRB1*0401 Positive Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-99-C-0159
, NCI-T99-0079, T99-0079, NCT00019994
10.
Phase II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides From MART-1:26-35, gp100:209-217, and Tyrosinase:368-372 and Treated Ex Vivo With CD40-Ligand and Interferon Gamma, Followed By Interleukin-2 In Vivo in HLA-A2.1 Positive Patients With Stage III or IV Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
LAC-USC-10M991
, NCI-G00-1837, NCI-T99-0102, NCT00006113, T99-0102
11.
Phase II Randomized Study of Immunization With an HLA-A2 Multiepitope Peptide Vaccine Comprising MART-1:27-35, gp100:209-217 (210M), and Tyrosinase:368-376 (370D) Peptides Alone or in Combination With Sargramostim (GM-CSF) and/or Interferon alfa-2b in HLA-A2 Positive Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
E-1696
, NCT00006385, E1696
12.
Phase II Study of gp100:209-217 (210M) Antigen and MART-1:26-35 (27L) Antigen Emulsified in Montanide ISA-51 in Patients With Metastatic Ocular Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-01-C-0074
, NCI-2910, 2910, NCT00020475
13.
Phase II Randomized Adjuvant Study of Vaccination With Tyrosinase, gp100, and MART-1 Peptides Emulsified With Montanide ISA-51 With Interleukin-12 and Either Alum Adjuvant or Sargramostim (GM-CSF) in Patients With Resected Stage IIB, IIC, III, or IV Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
LAC-USC-10M011
, LAC-USC-IRB-013030, NCI-5506, NCT00031733, 5506
14.
Phase II Randomized Study of Immunization With MART-1:27-35, 27-35 (27L):MART-1, or MART-1:26-35 (27L) Peptide or the Combination of 27-35 (27L):MART-1 and gp100:209-217 (210M) Antigen Peptides in HLA-A*0201-Positive Patients at High Risk for Recurrence of Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
Over 16
Sponsor:
NCI
Protocol IDs:
NCI-03-C-0172
, NCI-6211, 6211, NCT00062218
15.
Phase II Randomized Study of Immunization With MAGE-3, Melan-A, gp100 Antigen, and NA17-A Peptide-Pulsed Autologous Peripheral Blood Mononuclear Cells and Interleukin-12 With or Without Low-Dose Interleukin-2 in Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UCCRC-11447A
, NCI-1330, NCT00064168, 1330
16.
Phase II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) and Peptide Vaccine Comprising Tyrosinase, gp100 Antigen, and MART-1 Antigen Emulsified in Montanide ISA-51 in Patients With Resected Stage III or IV Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Temporarily closed
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
MCC-15241
, MDX-010-16, NCI-6446, 6446, NCT00084656, LAC-USC-10M036
17.
Phase II Randomized Continuation Study of a Vaccine Comprising Tyrosinase Peptide, gp100 Antigen, and MART-1 Antigen Emulsified With Montanide ISA-51 and ISA-51 VG With or Without Sargramostim (GM-CSF) in Patients With Resected Stage IIB, IIC, III, or IV Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
LAC-USC-10M038
, LAC-USC-042011, LAC-USC-0A1033, NCI-6618, 6618, NCT00089063
18.
Phase II Randomized Study of Vaccination Comprising gp100 and MART-1 Peptide Vaccines Emulsified in Montanide ISA-51 With or Without High-Dose Interleukin-2 After Lymphodepleting Chemotherapy and Reinfusion of Autologous T-Regulatory-Depleted Lymphocytes in Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-06-C-0028
, 7547, NCI-7547, NCI-P6574, NCT00303836
19.
Phase II Study of Recombinant LMB-2 Immunotoxin and Peptide Vaccination Comprising gp100:209-217 (210M) Antigen, MART-1:27-35 Antigen, and Montanide ISA-51 in Patients With Progressive Unresectable Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-06-C-0041
, 7542, NCI-7542, NCI-P6702, NCT00295958
20.
Phase II Study of MART-1/gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Matured With a Cytokine Cocktail in Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
LAC-USC-10M-03-1
, 6262, NCI-6262, LAC-USC-033307, NCT00334776
21.
Phase I Study of Immunization with Recombinant Fowlpox Virus Encoding the MART-1 Melanoma Antigen with or without Concomitant IL-2 in Patients with Metastatic Melanoma (Summary Last Modified 01/00)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
over 18
Sponsor:
NCI
Protocol IDs:
NCI-95-C-0032D
, NCI-T96-0026N, T96-0026
22.
Phase I Study of MART-1 Human Melanoma Peptide Vaccine in Metastatic Melanoma (Summary Last Modified 01/2000)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-95-C-0071C
, NCI-T94-0178N, T94-0178
23.
Phase I Study of Immunization with Recombinant Vaccinia Virus Encoding the MART-1 Melanoma Antigen with or without Concomitant IL-2 in Patients with Metastatic Melanoma (Summary Last Modified 03/1999)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
over 18
Sponsor:
NCI
Protocol IDs:
NCI-95-C-0068C
, NCI-T94-0137N, T94-0137
24.
Phase I Study of Immunization with Adenovirus Encoding the MART-1 Melanoma Antigen for Refractory Metastatic Melanoma (Summary Last Modified 12/1999)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-95-C-0079D
, NCI-T94-0195N, T94-0195
25.
Phase I Study of IL-12 Administered with a MART-1 Peptide Vaccine in Patients with Refractory Metastatic Melanoma (Summary Last Modified 11/1999)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-95-C-0143B
, NCI-T95-0039N, T95-0039
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
